Clinical Trial Update: Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a single-dose cyclophosphamide plus pembrolizumab in metastatic triple negative breast cancer has completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-08-03